A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration

Health Technology Assessment

Volumn 12, Issue 27, 2008, Pages

  Karnon, J ^a,h   Czoski Murray, C ^a   Smith, K ^a   Brand, C ^b   Chakravarthy, U ^c   Davis, S ^a   Bansback, N ^a   Beverley, C ^a   Bird, A ^d   Harding, S ^e   Chisholm, I ^f   Yang, Y C ^g  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g Wolverhampton Eye Infirmary   (United Kingdom)

^h UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; ANTIOXIDANT; BEVACIZUMAB; CORTICOSTEROID; PEGAPTANIB; PLACEBO; RANUBIZIMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VERTEPORFIN; VITAMIN; ZINC;

ARTICLE; BLINDNESS; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DRUG BINDING SITE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK POPULATION; HUMAN; INCIDENCE; LASER COAGULATION; MONOTHERAPY; MORTALITY; PHOTODYNAMIC THERAPY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOM SAMPLE; RESOURCE ALLOCATION; RETINA MACULA AGE RELATED DEGENERATION; SCREENING TEST; SENSITIVITY ANALYSIS; STATISTICAL PARAMETERS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; AGED; BIOMEDICAL TECHNOLOGY ASSESSMENT; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH PERSONNEL ATTITUDE; LITERATURE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; QUESTIONNAIRE; RETINA MACULA DEGENERATION; RISK FACTOR; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; INCIDENCE; MACULAR DEGENERATION; MASS SCREENING; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; REVIEW LITERATURE AS TOPIC; RISK FACTORS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 48349093085     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta12270     Document Type: Article

References (114)

1. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-74.
2. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 2003;18:845-54.
3. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980;24 (Suppl):335-610.
4. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003; 87:312-17.
5. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-72.
6. Chang TS, Hay D, Courtright P. Age-related macular degeneration in Chinese-Canadians. Can J Ophthalmol 1999;34:266-71.
7. Bressler NM, Munoz B, Maguire MG, Vitale SE, Schein OD, Taylor HR, et al. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. Arch Ophthalmol 1995;113:301-8.
8. Wilson J, Junger G. Principles and practice of screening for disease. Public Health Paper 34. Geneva: World Health Organization; 1968.
9. National Screening Committee. NSC criteria for appraising the viability, effectiveness and appropriateness of a screening programme. URL: http://www.nsc.nhs.uk/pdfs/Criteria.pdf. Accessed 7 July 2007.
10. Bartlett H, Eperjesi F. Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials. Ophthalmic Physiol Opt 2003;23:383-99.
11. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001; 108:697-704.
12. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996;276:1141-6.
13. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 1996;276:1147-51.
14. Age-Related Eye Disease Research Study Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology 2000;107: 2224-32.
15. Delcourt C, Diaz JL, Ponton-Sanchez A, Papoz L. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liées à l'Age. Arch Ophthalmol 1998;116:1031-5.
16. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol 1996;114:1193-6.
17. Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, Vernet MH, et al. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol 2001;8:237-49.
18. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2003; 110:636-43.
19. Klein R, Klein BE, Jensen SC. The relation of cardiovascular disease and its risk factors to the 5-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997; 104:1804-12.
20. Klein R, Klein BE, Wong TY, Tomany SC, Cruickshanks KJ. The association of cataract and cataract surgery with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2002;120:1551-8.
21. Chaine G, Hullo A, Sahel J, Soubrane G, Espinasse-Berrod MA, Schutz D, et al. Case-control study of the risk factors for age related macular degeneration. France-DMLA Study Group. Br J Ophthalmol 1998;82:996-1002.
22. Buch H, Nielsen N, Vinding T, Jensen G, Prause JU, la Cour M. 14-Year incidence, progression and visual morbidity of age-related maculopathy. Ophthalmology 2005;112:787-98.
23. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study [published erratum appears in Ophthalmology 2002;109:1588]. Ophthalmology 2002;109:1092-7.
24. Tomany SC, Klein R, Klein BE. The relation of coffee and caffeine to the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Am J Ophthalmol 2001;132:271-3.
25. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
26. Sparrow JM, Dickinson AJ, Duke AM, Thompson JR, Gibson JM, Rosenthal AR. Seven year follow-up of age-related maculopathy in an elderly British population. Eye 1997;11(Pt 3):315-24.
27. Age-Related Eye Disease Study Research Group. Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19. Ophthalmology 2005;112:533-9.
28. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1998;105:11-23.
29. Burgess DB, Hawkins BS, Jefferys JL, Bressler NM, Bressler SB, Hiner CJ, et al. 5-Year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol 1993; 111:1189-99.
30. Wilkinson CP, Hawkins BS, Javornik NB, Newhouse MM, Keller JA, Bressler NM, et al. Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. Arch Ophthalmol 1996; 114:677-88.
31. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol 1997;115:741-7.
32. Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL. Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 1988; 106:1537-42.
33. Sunness JS, Gonzalez-Baron J, Bressler NM, Hawkins B, Applegate CA. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999;106:910-19.
34. Pauleikhoff D, Radermacher M, Spital G, Muller C, Brumm G, Lommatzsch A, et al. Visual prognosis of second eyes in patients with unilateral late exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:539-42.
35. Baun O, Vinding T, Krogh E. Natural course in fellow eyes of patients with unilateral age-related exudative maculopathy. A fluorescein angiographic 4-year follow-up of 45 patients. Acta Ophthalmol 1993;71:398-401.
36. Wang JJ, Foran S, Smith W, Mitchell P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmology 2003; 121:658-63.
37. Holz FG, Wolfensberger TJ, Piguet B, Gross-Jendroska M, Wells JA, Minassian DC, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 1994;101:1522-8.
38. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye 1988;2:552-77.
39. Schatz H, McDonald HR. Atrophic macular degeneration: rate of spread of geographic atrophy and visual loss. Ophthalmology 1989; 96:1551.
40. Ali F, Chan WC, Stevenson MR, Muldrew KA, Chakravarthy U. Morphometric analysis of angiograms of exudative lesions in age-related macular degeneration. Arch Ophthalmol 2004; 122:710-15.
41. Sunness JS. The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol Vis 1999; 5:25.
42. Sunness JS, Gonzalez-Baron J, Applegate CA, Bressler NM, Tian Y, Hawkins B, et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999; 106:1768-79.
43. Stevenson MR, Hart PM, Chakravarthy U, MacKenzie G, Bird AC, Owens SL, et al. Visual functioning and quality of life in the SubFoveal Radiotherapy Study (SFRADS): SFRADS report 2. Br J Ophthalmol 2005;89:1045-51.
44. Zaidi FH, Cheong-Leen R, Gair EJ, Weir R, Sharkawi E, Lee N, et al. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London Survey. Eye 2004;18:503-8.
45. Barthes A, Conrath J, Rasigni M, Adel M, Petrakian JP. Mathematical morphology in computerized analysis of angiograms in age-related macular degeneration. Med Phys 2001; 28:2410-19.
46. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986; 104:513-14.
47. Schmitt NJ, Grover DA, Feldon SE. The Eger Macular Stressometer: pilot study. Am J Ophthalmol 2003;136:314-17.
48. Lafaut BA, De Backer E, Kohno T, De Laey JJ, Meire FM. Indocyanine green angiography in Sorsby's fundus dystrophy. Graefes Arch Clin Exp Ophthalmol 2000;238:158-62.
49. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-14.
50. Evans JR. Antioxidant vitamin and mineral supplements for age-related macular degeneration (Cochrane Review) In The Cochrane Library, Issue 1. Chichester: Wiley; 2004.
51. Teikari JM, Laatikainen L, Virtamo J, Haukka J, Rautalahti M, Liesto K, et al. Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy. Acta Ophthalmol Scand 1998;76:224-9.
52. ClinicalTrials.gov. Open-label posterior juxtascleral injections of anecortave acetate 15 mg dose for long term use in patients with AMD. URL: http://www.clinicaltrials.gov/ct/show/NCT00065728;jsessionid= 547BE5D966347E4DA5750BE230BB9F66?order=1. Accessed 7 July 2007.
53. Pulido JS, Sanders DR, Klingel R. Rheopheresis for age-related macular degeneration: clinical results and putative mechanism of action. Can J Ophthalmol 2005;40:332-40.
54. Pulido JS, Multicenter Investigation of Rheopheresis for AMD (MIRA). Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc 2002; 100:85-106.
55. Panel discussion. Evolving treatment strategies for exudative AMD. The combination of verteporfin PDT and triamcinolone is already changing practice patterns. Retinal Physician 2005. URL: http://www.retinalphysician.com/article.aspx?article=100108. Accessed 17 April 2008.
56. Jonas JB, Kreissig I, Degenring RF. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br J Ophthalmol 2004; 88:1557-62.
57. Bhavsar A. Combined verteporfin photodynamic therapy and intravitreal triamcinolone in the treatment of minimally classic subfoveal CNV with or without RAP lesions. AAO poster presentation P0163. 2004.
58. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularisation due to age-related macular degeneration. Ophthalmology 2006; 113:14-22.
59. Eye facts. Anti-VEGF treatment for age-related macular degeneration. URL: https://secure3.aao.org/pdf/057052.pdf. Accessed 7 July 2007.
60. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
61. Genentech. Genentech granted six-month priority review for ranubizimab for the treatment of wet AMD. URL: http://www.mdsupport.org/. Accessed 7 July 2007.
62. Roberts D. Avastin for wet AMD? February 2007. URL: http://www.mdsupport.org/library/avastin.html. Accessed 7 July 2007.
63. Thomas MA, Ibanez HE. Subretinal endophotocoagulation in the treatment of choroidal neovascularization. Am J Ophthalmol 1993; 116:279-85.
64. van Meurs JC, van den Biesen PR. Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: short-term follow-up. Am J Ophthalmol 2003; 136:688-95.
65. Moss SM, Gray A, Legood R, Henstock E. Evaluation of HPV/LBC Cervical Screening Pilot Studies. First report to the Department of Health on evaluation of LBC. London: Department of Health; 2002.
66. Roderick P, Davies R, Raftery J, Crabbe D, Bhandari P, Patel P. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete event simulation model. Health Technol Assess 2003; 7(6).
67. Goverdhan SV, Booth AJ, Luff AJ, Lotery AJ. Age-related macular degeneration. Where are we now? Optometry Today 2004; (17 December) 39-43.
68. Busbee B, Brown MM, Brown GC, Sharma S. CME review: a cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularisation. Retina 2003;23:279-87.
69. Bonastre J, Le Pen C, Soubrane G, Quentel G. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003;21:181-90.
70. Sharma S, Bakal J, Sharma SM, Covert D, Shah GK. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005;40:369-77.
71. van Leeuwen R, Chakravarthy U, Vingerling J, Brussee C, Hooghart A, Mulder P, et al. Grading of age-related maculopathy for epidemiological studies - is digital imaging as good as 35-mm film? Ophthalmology 2003;110:1540-4.
72. Pollack A. Genentech in competition with itself on eye drug. New York Times 27 September, 2005. URL: http://www.nytimes.com/2005/09/27/ business/27place.html. Accessed 17 April 2008.
73. Cooke R. I can see clearly now. At last, therapies improve vision lost to macular degeneration. AARP Bull 2005. URL: http://www.aarp.org/ bulletin/yourhealth/macular.html. Accessed 17 April 2008.
74. EyeTech. Press release: Safety profile of Pegaptanib® (pegaptanib sodium injection) in the treatment of neovascular age-related macular degeneration (AMD) maintained for two years. New York, 2 May, 2005. URL: http://www.mpmcapital.com/newsroom/news/050502ii.pdf. Accessed 7 July 2007.
75. Meads C, Moore D. The clinical effectiveness and cost utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2001;7(9).
76. Espallargues M, Czoski-Murray C, Bansback N, Carlton J, Lewis G, Hughes L, et al. The impact of age related macular degeneration on health state utility values. Invest Ophthalmol Vis Sci 2005; 46:4016-23.
77. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
78. Brown MM, Brown GC, Sharma S, Landy J, Bakal J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002;120:481-4.
79. Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. Br J Ophthalmol 2004;88:212-17.
80. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 1996;80:9-14.
81. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 2006; 9:113-20.
82. Towse A, Devlin N, Pritchard C, editors. Cost effectiveness thresholds: economic and ethical issues. London: Office for Health Economics/King's Fund; 2002.
83. Stevenson M, Oakley J, Chilcott J. Gaussian process modelling in conjunction with individual patient simulation modelling. A case study describing the calculation of cost-effectiveness ratios for the treatment of osteoporosis. Med Decis Making 2004;24:89-100.
84. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003; 6:9-17.
85. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 2000; 84:244-50.
86. Vaclavik V, Vujosevic S, Dandekar SS, Bunce C, Peto T, Bird AC. Autofluorescence imaging in age-related macular degeneration complicated by choroidal neovascularization. A prospective study. Ophthalmology 2008;115:342-6.
87. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64.
88. Woods RL, Tregear SJ, Mitchell RA. Screening for ophthalmic disease in older subjects using visual acuity and contrast sensitivity. Ophthalmology 1998;105:2318-232.
89. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205-10.
90. Das BN, Thompson JR, Patel R, Rosenthal AR. The prevalence of eye disease in Leicester: a comparison of adults of Asian and European descent. J R Soc Med 1994;87:219-22.
91. Dickinson AJ, Sparrow JM, Duke AM, Thompson JR, Gibson JM, Rosenthal AR. Prevalence of age-related maculopathy at two points in time in an elderly British population. Eye 1997;11(Pt 3):301-14.
92. Vinding T. Visual impairment of age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol 1990; 68:162-7.
93. Klaver CCW, Wolfs RCW, Vingerling JR, Hofman A, De Jong PTVM. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study. Arch Ophthalmol 1998; 116:653-8.
94. Klaver CC, Assink JJ, van Leeuwen R, Wolfs RC, Vingerling JR, Stijnen T, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2001; 42:2237-41.
95. Maguire MG. More pieces for the age-related macular degeneration puzzle, Ophthalmology 1997; 104:5-6.
96. Schachat AP, Hyman L, Leske MC, Connell AM, Wu SY. Features of age-related macular degeneration in a black population. The Barbados Eye Study Group. Arch Ophthalmol 1995; 113:728-35.
97. Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000; 118:264-9.
98. Reidy A, Minassian DC, Vafidis G, Joseph J, Farrow S, Wu J, et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ 1998;316:1643-6.
99. Mitchell RA. Prevalence of age related macular degeneration in persons aged 50 years and over resident in Australia. J Epidemiol Commun Health 1993;47:42-5.
100. Munier A, Gunning T, Kenny D, O'Keefe M. Causes of blindness in the adult population of the Republic of Ireland. Br J Ophthalmol 1998; 82:630-3.
101. Foran S, Wang JJ, Mitchell P. Causes of incident visual impairment: the Blue Mountains Eye Study. Arch Ophthalmol 2002;120:613-19.
102. Huang GH, Klein R, Klein BE, Tomany SC. Birth cohort effect on prevalence of age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 2003;157:721-9.
103. Gibson JM, Rosenthal AR, Lavery J. A study of the prevalence of eye disease in the elderly in an English community. Trans Ophthalmol Soc UK 1985; 104(Pt 2):196-203.
104. Cruickshanks KJ, Hamman RF, Klein R, Nondahl DM, Shetterly SM. The prevalence of age-related maculopathy by geographic region and ethnicity. The Colorado-Wisconsin Study of Age-Related Maculopathy. Arch Ophthalmol 1997; 115:242-50.
105. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000;107:1593-600.
106. Foran S, Wang JJ, Mitchell P. Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003;10:215-25.
107. Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 2001; 108:2347-57.
108. Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clinical Exp Ophthalmol 2000; 28:268-73.
109. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102:1450-60.
110. Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ. Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 2003;110:1534-9.
111. Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. Am J Epidemiol 2002;156:589-98.
112. Rahmani B, Tielsch JM, Katz J, Gottsch J, Quigley H, Javitt J, et al. The cause-specific prevalence of visual impairment in an urban population: the Baltimore Eye Survey. Ophthalmology 1996; 103:1721-6.
113. Farber MD. National Registry for the Blind in Israel: estimation of prevalence and incidence rates and causes of blindness. Ophthalmic Epidemiol 2003;10:267-77.
114. Frennesson CI. Photodynamic therapy with verteporfin in patients with age-related macular degeneration and juxtafoveal choroidal neovascularisation. Acta Ophthalmol Scand 2004;82:651-5.